We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Global Blood Therapeutics’ GBT440 has become the first potential treatment for sickle cell disease to be accepted onto the European Medicines Agency’s regulatory support programme PRIME